



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_209_25

You asked:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Spesolimab

Our response:

Please find below as requested a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1st February 2025 to 30th April 2025 the latest 3 months available

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	60
Apremilast	50
Bimekizumab	17
Brodalumab	**
Certolizumab	**
Deucravacitinib	17
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	51
Infliximab - Remicade	0
Infliximab Biosimilar	**
Ixekizumab	21
Risankizumab	60
Secukinumab	10
Tildrakizumab	13
Ustekinumab - Stelara	**
Ustekinumab Biosimilar	37
Spesolimab	0